Cefiderocol Activity Against Clinical Pseudomonas aeruginosa Isolates Exhibiting Ceftolozane-Tazobactam Resistance

Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the Antibiotic

(2021) Ana Paula Streling et al.   CLINICAL INFECTIOUS DISEASES

In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam

(2021) Abigail M. Rubio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Structural basis of reduced susceptibility to ceftazidime–avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion

(2020) Akito Kawai et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime

(2020) Ryan K Shields et al.   CLINICAL INFECTIOUS DISEASES

Species Identification and Antibiotic Resistance Prediction by Analysis of Whole Genome Sequence Data Using ARESdb – An Analysis of Isolates from the Unyvero Lower Respiratory Tract Infection Trial

(2020) Ines Ferreira et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Adding insult to injury: mechanistic basis for how AmpC mutations allow Pseudomonas aeruginosa to accelerate cephalosporin hydrolysis and evade avibactam

(2020) Cole L. Slater et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3

(2020) Saquib Malik et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Modifiable Risk Factors for the Emergence of Ceftolozane-Tazobactam Resistance

(2020) Pranita D Tamma et al.   CLINICAL INFECTIOUS DISEASES

Resistance to Novel β-Lactam–β-Lactamase Inhibitor Combinations

(2020) Krisztina M. Papp-Wallace et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-negative Bacilli: A Comparison of Disk Diffusion to Broth Microdilution

(2020) C. Paul Morris et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam

(2018) Melissa D. Barnes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

TonB-Dependent Receptor Repertoire of Pseudomonas aeruginosa for Uptake of Siderophore-Drug Conjugates

(2018) Alexandre Luscher et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

696. Mechanism of Cefiderocol high MIC mutants obtained in non-clinical FoR studies

(2018) Akinobu Ito et al.   Open Forum Infectious Diseases

Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy

(2015) Aryun Kim et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins

(2015) M. Berrazeg et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City

(2015) Amabel Lapuebla et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Involvement of Fe Uptake Systems and AmpC β-Lactamase in Susceptibility to the Siderophore Monosulfactam BAL30072 in Pseudomonas aeruginosa

(2013) Christian van Delden et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinically Relevant Gram-Negative Resistance Mechanisms Have No Effect on the Efficacy of MC-1, a Novel Siderophore-Conjugated Monocarbam

(2012) Craig J. McPherson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY